FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076526319> ?p ?o ?g. }

• W2076526319 endingPage "1069" @default.
• W2076526319 startingPage "1061" @default.
• W2076526319 abstract "Study Objective To investigate oseltamivir and oseltamivir carboxylate pharmacokinetics in critically ill patients who were receiving continuous venovenous hemodialysis (CVVHD) and/or extracorporeal membrane oxygenation (ECMO). Design Prospective, open-label, pharmacokinetic study. Setting Intensive care units of an academic medical center. Patients Thirteen critically ill patients aged 13 years or older with suspected or confirmed H1N1 influenza who had a prescription for oseltamivir and were concurrently receiving CVVHD and/or ECMO between October 2009 and January 2010. Intervention Oseltamivir 150 mg was administered nasogastrically or nasoenterically every 12 hours. Blood samples were collected at baseline and at 1, 2, 4, 6, 8, 10, and 12 hours after administration of the fourth oseltamivir dose or subsequent doses. In patients receiving CVVHD, effluent also was collected at the same time points. Urine was collected throughout the 12-hour dosing interval. Measurements and Main Results Eight patients received CVVHD only, four patients received both CVVHD and ECMO, and one patient received ECMO only. Pharmacokinetic parameters for the patient who received only ECMO were not reported. The median maximum plasma concentration and area under the plasma concentration–time curve for the 12-hour dosing interval (AUC0–12) for the remaining 12 patients were 83.4 ng/ml and 216 ng•hour/ml, respectively, for oseltamivir and 2000 ng/ml and 21,500 ng•hour/ml, respectively, for oseltamivir carboxylate. Mean clearance due to CVVHD was 33.8 ml/minute for oseltamivir and 50.2 ml/minute for oseltamivir carboxylate. For patients who received ECMO, no substantial differences between pre- and post-ECMO oxygenator plasma concentrations were found for oseltamivir or oseltamivir carboxylate. Conclusion Although the optimal pharmacokinetic-pharmacodynamic targets for oseltamivir carboxylate remain unclear, in the patients receiving CVVHD with or without ECMO, a regimen of oseltamivir 150 mg every 12 hours yielded a median oseltamivir carboxylate AUC0–12 considerably higher than would be expected in non–critically ill patients receiving the same dosage regimen." @default.
• W2076526319 created "2016-06-24" @default.
• W2076526319 creator A5013348917 @default.
• W2076526319 creator A5025295131 @default.
• W2076526319 creator A5040889843 @default.
• W2076526319 creator A5062490810 @default.
• W2076526319 creator A5071415825 @default.
• W2076526319 creator A5086759839 @default.
• W2076526319 creator A5089467056 @default.
• W2076526319 date "2012-12-01" @default.
• W2076526319 modified "2023-10-06" @default.
• W2076526319 title "Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis and/or Extracorporeal Membrane Oxygenation" @default.
• W2076526319 cites W1965998468 @default.
• W2076526319 cites W1983960319 @default.
• W2076526319 cites W2007304817 @default.
• W2076526319 cites W2025744709 @default.
• W2076526319 cites W2026315288 @default.
• W2076526319 cites W2036520108 @default.
• W2076526319 cites W2038519725 @default.
• W2076526319 cites W2044526347 @default.
• W2076526319 cites W2047615680 @default.
• W2076526319 cites W2054650621 @default.
• W2076526319 cites W2081460129 @default.
• W2076526319 cites W2081518976 @default.
• W2076526319 cites W2088477847 @default.
• W2076526319 cites W2101373870 @default.
• W2076526319 cites W2111179202 @default.
• W2076526319 cites W2112166111 @default.
• W2076526319 cites W2118353440 @default.
• W2076526319 cites W2118764399 @default.
• W2076526319 cites W2128832687 @default.
• W2076526319 cites W2133162236 @default.
• W2076526319 cites W2139837686 @default.
• W2076526319 cites W2149223126 @default.
• W2076526319 cites W2156695158 @default.
• W2076526319 cites W2168610454 @default.
• W2076526319 cites W2170186039 @default.
• W2076526319 cites W2170223934 @default.
• W2076526319 cites W2502670554 @default.
• W2076526319 doi "https://doi.org/10.1002/phar.1151" @default.
• W2076526319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23208833" @default.
• W2076526319 hasPublicationYear "2012" @default.
• W2076526319 type Work @default.
• W2076526319 sameAs 2076526319 @default.
• W2076526319 citedByCount "37" @default.
• W2076526319 countsByYear W20765263192013 @default.
• W2076526319 countsByYear W20765263192014 @default.
• W2076526319 countsByYear W20765263192015 @default.
• W2076526319 countsByYear W20765263192016 @default.
• W2076526319 countsByYear W20765263192017 @default.
• W2076526319 countsByYear W20765263192018 @default.
• W2076526319 countsByYear W20765263192019 @default.
• W2076526319 countsByYear W20765263192020 @default.
• W2076526319 countsByYear W20765263192021 @default.
• W2076526319 countsByYear W20765263192022 @default.
• W2076526319 countsByYear W20765263192023 @default.
• W2076526319 crossrefType "journal-article" @default.
• W2076526319 hasAuthorship W2076526319A5013348917 @default.
• W2076526319 hasAuthorship W2076526319A5025295131 @default.
• W2076526319 hasAuthorship W2076526319A5040889843 @default.
• W2076526319 hasAuthorship W2076526319A5062490810 @default.
• W2076526319 hasAuthorship W2076526319A5071415825 @default.
• W2076526319 hasAuthorship W2076526319A5086759839 @default.
• W2076526319 hasAuthorship W2076526319A5089467056 @default.
• W2076526319 hasBestOaLocation W20765263192 @default.
• W2076526319 hasConcept C112705442 @default.
• W2076526319 hasConcept C126322002 @default.
• W2076526319 hasConcept C2776858399 @default.
• W2076526319 hasConcept C2777288759 @default.
• W2076526319 hasConcept C2777538117 @default.
• W2076526319 hasConcept C2778063415 @default.
• W2076526319 hasConcept C2779134260 @default.
• W2076526319 hasConcept C2780374985 @default.
• W2076526319 hasConcept C3008058167 @default.
• W2076526319 hasConcept C42219234 @default.
• W2076526319 hasConcept C524204448 @default.
• W2076526319 hasConcept C71924100 @default.
• W2076526319 hasConceptScore W2076526319C112705442 @default.
• W2076526319 hasConceptScore W2076526319C126322002 @default.
• W2076526319 hasConceptScore W2076526319C2776858399 @default.
• W2076526319 hasConceptScore W2076526319C2777288759 @default.
• W2076526319 hasConceptScore W2076526319C2777538117 @default.
• W2076526319 hasConceptScore W2076526319C2778063415 @default.
• W2076526319 hasConceptScore W2076526319C2779134260 @default.
• W2076526319 hasConceptScore W2076526319C2780374985 @default.
• W2076526319 hasConceptScore W2076526319C3008058167 @default.
• W2076526319 hasConceptScore W2076526319C42219234 @default.
• W2076526319 hasConceptScore W2076526319C524204448 @default.
• W2076526319 hasConceptScore W2076526319C71924100 @default.
• W2076526319 hasIssue "12" @default.
• W2076526319 hasLocation W20765263191 @default.
• W2076526319 hasLocation W20765263192 @default.
• W2076526319 hasLocation W20765263193 @default.
• W2076526319 hasOpenAccess W2076526319 @default.
• W2076526319 hasPrimaryLocation W20765263191 @default.
• W2076526319 hasRelatedWork W1968377412 @default.
• W2076526319 hasRelatedWork W2027368298 @default.
• W2076526319 hasRelatedWork W2083271125 @default.

• next